Our chances are excellent but not 100% . But I thi
Post# of 148181
(Total Views: 786)
Posted On: 12/08/2020 9:53:23 PM
Our chances are excellent but not 100% . But I think 80-100%
100% correlation between this list and an EUA approval
5 drug candidates on the list have not received an EUA
3 drug candidates seem imminent
What this pandemic has taught us is that the government has to plan ahead. 3M Blogger Rhonda Butler had unwittingly discovered how to identify drugs the government is considering for approval. She has cracked the code giving investors a bonafide list to pick winners from. The Centers for Medicare and Medicade Services (CMS) is required under law to develop a classification system known as Diagnosis Related Groups (DRGs). These DRG classifications are the constants that payment formulas and algorithms use to create reimbursement amounts within the hospital system. On July 31st in her blog she highlighted Remdesivir ((Veklury), Sarilumab (KEVZARA®), Tocilizumab (ACTEMRA®), and Convalescent plasma. Half of these drugs were approved in the coming month. Two drugs are very high probable picks for approval so investors should read on.
Back Testing
In order to test this theory, we have to look at what the report said and then trace what happened. First we will look at what drugs were on the report but failed to obtain approval. Roche Holdings (OTCMKTS: RBBHY) drug Tocilizumab failed its clinical trials on July 29th which was just a couple of days before the update. It’s conceivable that the FDA had correspondence with the CMS to make sure it was in the system in case results had gone the opposite way and ended up with an approval. Sanofi (NYSE: SNY) and Regeneron’s (NASDAQ: REGN) drug Sarilumab failed on June 6th but they still had another ongoing trial they thought was promising. On September 1st they announced Sarilumab’s second failure. On August 23rd the FDA issued an EUA for Convalescent plasma. On August 28th the FDA expanded the EUA for Remdesivir. It’s pretty clear that absent a trial failure the FDA is communicating with CMS to ensure that the coding in the system is ready to go in the event of good trial results. There seemed to be a correlation that shortly after the coding the drugs received an EUA. Right now the theory is batting .500.
100% correlation between this list and an EUA approval
5 drug candidates on the list have not received an EUA
3 drug candidates seem imminent
What this pandemic has taught us is that the government has to plan ahead. 3M Blogger Rhonda Butler had unwittingly discovered how to identify drugs the government is considering for approval. She has cracked the code giving investors a bonafide list to pick winners from. The Centers for Medicare and Medicade Services (CMS) is required under law to develop a classification system known as Diagnosis Related Groups (DRGs). These DRG classifications are the constants that payment formulas and algorithms use to create reimbursement amounts within the hospital system. On July 31st in her blog she highlighted Remdesivir ((Veklury), Sarilumab (KEVZARA®), Tocilizumab (ACTEMRA®), and Convalescent plasma. Half of these drugs were approved in the coming month. Two drugs are very high probable picks for approval so investors should read on.
Back Testing
In order to test this theory, we have to look at what the report said and then trace what happened. First we will look at what drugs were on the report but failed to obtain approval. Roche Holdings (OTCMKTS: RBBHY) drug Tocilizumab failed its clinical trials on July 29th which was just a couple of days before the update. It’s conceivable that the FDA had correspondence with the CMS to make sure it was in the system in case results had gone the opposite way and ended up with an approval. Sanofi (NYSE: SNY) and Regeneron’s (NASDAQ: REGN) drug Sarilumab failed on June 6th but they still had another ongoing trial they thought was promising. On September 1st they announced Sarilumab’s second failure. On August 23rd the FDA issued an EUA for Convalescent plasma. On August 28th the FDA expanded the EUA for Remdesivir. It’s pretty clear that absent a trial failure the FDA is communicating with CMS to ensure that the coding in the system is ready to go in the event of good trial results. There seemed to be a correlation that shortly after the coding the drugs received an EUA. Right now the theory is batting .500.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼